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Cervical cancer is initiated by high-risk types of the human papillomavirus (hrHPV) and develops via
precursor stages, called cervical intraepithelial neoplasia (CIN). High-grade CIN lesions are considered
true precancerous lesions when the viral oncogenes E6 and E7 are aberrantly expressed in the dividing
cells. This results in abolishment of normal cell cycle control via p53 and pRb degradation. However, it
has become clear that these viral oncogenes possess additional oncogenic properties, including inter-
ference with the DNA methylation machinery and mitotic checkpoints. Identiﬁcation of the resulting
molecular events leading to high-grade neoplasia will 1) increase our understanding of cervical carci-
nogenesis, 2) yield biomarkers for early diagnosis, and 3) identify therapeutic targets for HPV-induced
(pre) cancerous lesions.
This review will brieﬂy summarise current advances in our understanding of the molecular altera-
tions in the host cell genome that occur during HPV-induced carcinogenesis.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Contents1. Cervical carcinogenesis and hrHPV-induced transformation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
2. DNA methylation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 85
3. Chromosomal alterations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
4. Mutations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
5. Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Competing interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 871. Cervical carcinogenesis and hrHPV-induced transformation
Cervical carcinomas are caused by infection with hrHPV types
and can be divided in two main histotypes, squamous cell carci-
nomas (SCCs; 80%) and adenocarcinomas (AdCAs; 15–20%) [1].
SCCs develop via well recognised precursor lesions, called cervical
intraepithelial neoplasia (CIN), that according to severity are gra-
ded from 1 (mild dysplasia) to 3 (severe dysplasia). Together CIN2
and CIN3 lesions are referred to as high-grade CIN lesions (hgCIN).
Little is known about AdCA precursor lesions up to adenocarci-
noma-in-situ (ACIS). Progression of hrHPV-infected epithelial cellsr B.V. This is an open access article
eenbergen).to invasive cancer is a long term process associated with the ac-
cumulation of DNA alterations in host cell genes. These alterations
involve both epigenetic and genetic changes in oncogenes and
tumour suppressor genes. Epigenetic changes affect gene expres-
sion by mechanisms other than changes in the underlying DNA
sequence, whereas genetic changes are considered adaptations in
the DNA sequence itself.
The process of HPV-mediated transformation and its associated
accumulation of crucial (epi)genetic events over time can be mi-
micked in vitro by long term passaging of primary keratinocytes
infected with hrHPV. Thereby these in vitro models enable long-
itudinal and functional analysis of driver events.under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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One of the best studied epigenetic mechanisms is DNA me-
thylation, the covalent addition of a methyl group (-CH3) to cy-
tosines preceding guanines in the DNA sequence, called CpG di-
nucleotides. CpGs can be clustered in so-called CpG islands, which
are CpG-rich sequences frequently located in gene promoters. DNA
methyltransferases are the enzymes responsible for DNA methy-
lation. De novo DNA methyltransferases DNMT3A and B are in-
volved in the establishment of novel DNA methylation patterns,
whereas DNMT1 ensures proper maintenance and inheritance of
already established methylation patterns. During cancer develop-
ment local hypermethylation of the CpG islands located in gene
promoter regions can lead to silencing of tumour suppressor genes
(reviewed in [2]).
Interestingly, hrHPV E6 and E7 have been found to directly
associate with and increase the activity of DNMTs [3–5]. Silencing
of E6 and E7 decreased methylation of tumour suppressor genes
and reversed the transformed phenotype of cervical cancer cells
[6]. The direct association between the enzymes responsible for
DNA methylation and HPV may (partly) explain why DNA hy-
permethylation is found to be a frequent event during cervical
carcinogenesis. In support of this HPV-positive head and neck
squamous cell carcinomas (HNSCC) showed higher overall me-
thylation rates compared to HPV-negative HNSCCs [7]. Together
these observations suggest that induction of DNA methylation
mediated silencing of tumour suppressor genes represents a se-
parate oncogenic property of HPV.
Methylation-mediated silencing of many protein-coding tu-
mour suppressor genes has been described in cervical (pre)cancer
(reviewed in [8,9]). Besides protein coding genes also methylation
mediated silencing of non-coding microRNAs (miRNAs) has been
detected in cervical lesions (reviewed in [10]). The level of me-
thylation was found to increase with severity of cervical disease
and within hgCIN lesions also with the duration of disease [11,12].
The functional relevance of these methylation events was de-
monstrated for part of these genes and miRNAs, including
C3ORF14, C13ORF18, CADM1, MAL, PRDM14, SFRP2, miR-124, miR-
203, and miR-375, using in vitromodels [13–22]. Moreover, in vitro
studies have shown that the onset of DNA methylation may differ
between genes, but that in all instances the methylation levels
increase during transformation [23,24]. Interestingly, the methy-
lation patterns were found to be mostly independent of the
hrHPV-type present [24]. A recent study in our group highlighted
the importance of methylation-mediated silencing of certain
miRNAs for the acquisition of anchorage independence during
HPV-induced transformation (unpublished data).3. Chromosomal alterations
When aberrantly expressed in dividing cells, e.g. due to viral
integration or methylation, both viral oncoproteins E6 and E7 are
known to induce DNA damage, centrosome abnormalities and
chromosomal segregation defects, thereby leading to chromoso-
mal instability (reviewed in [25,26]). Next to expression of viral
oncogenes, viral integration has been related to chromosomal in-
stability. Two recent independent studies describe that viral in-
tegration occurs close to or within ampliﬁed chromosomal regions
more often than expected by chance [27,28]. However, it remains a
matter of debate whether viral integration results in chromosomal
instability or whether chromosomal instability facilitates viral in-
tegration. The facts that the frequency of viral integration in-
creases with progression to cancer and that chromosomal in-
stability is also observed in cases without viral integration support
the latter [27,29,30].In 2014, Thomas et al. performed a meta-analysis using data from
studies that determined chromosomal changes by comparative
genomic hybridisation (CGH) in HPV-positive and -negative cancers
and in premalignant lesions of the anogenital tract (cervix, anus,
vagina, penis and vulva) [31]. In cervical SCC a gain of 3q was the
most frequently observed alteration in 55% of cases. Other common
alterations include loss of chromosome 3p and 11q, observed in 36%
and 33% of SCC. These ﬁndings are corroborated by recent exome-
sequencing studies [28,32]. Gain of 3q and loss of 3p and 11q were
less common in cervical AdCA, which instead more frequently
showed a gain at 17q (36%).
The three studies on hgCIN lesions that were available for this
meta-analysis showed that the most common alterations in SCC
were already observed in part of the hgCIN lesions (gain of 3q in
27%, loss of 3p and 11q in 8% and 15% respectively), suggesting these
alterations to be crucial and their presence is likely to reﬂect ad-
vanced hgCIN. Interestingly, when comparing chromosomal proﬁles
of histologically similar hgCIN lesions great heterogeneity was ob-
served [33]. Whereas part of the CIN lesions showed little to no
alterations, others had chromosomal proﬁles comparable to in-
vasive carcinomas. HgCIN lesions with these ‘cancer-like’ proﬁles
were found to most likely represent longer lasting, more advanced
lesions as indicated by the duration of preceding hrHPV infection
[34].
Although sample sizes of most individual studies did not allow
for reliable comparison between chromosomal proﬁles of lesions
with different HPV-types, Thomas et al. were able to investigate
this in their meta-analysis [31]. Gain of 3q was signiﬁcantly more
common in HPV16-induced squamous lesions, whereas gain of 17q
was more common in HPV18-induced AdCA compared to other
HPV types. This may reﬂect HPV type dependence, as supported by
recent in vitro work of our own group. It was found that the
number of observed chromosomal aberrations in HPV-im-
mortalised keratinocytes is HPV-type dependent and inversely
related to the viral immortalisation capacity [35].4. Mutations
The role of somatic mutations during HPV-induced carcino-
genesis has long remained inconclusive. Recent proﬁling of 301
cervical carcinomas using a mass spectrometry-based panel of
known somatic mutations (GynCarta 2.0, Sequenom) revealed
frequent mutations in PIK3CA (SCC 25%, AdCA 3%) and KRAS (SCC
11%, AdCA 24%) [36]. A comprehensive genomic landscape paper
on 115 cervical carcinomas revealed both known and novel re-
current mutations in cervical SCC, including mutations in EP300
(16%), FBXW7 (15%), PIK3CA (14%), HLA-B (9%), p53 (9%), MAPK1
(8%), PTEN (6%), ERBB2 (5%), STK11 (4%), NFE2L2 (4%) [28]. With
the exception of PIK3CA (16%), cervical AdCA harboured recurrent
mutations in another subset of genes including ELF3 (13%), KRAS
(8%), and CBFB (8%). In addition, differences in mutational sig-
natures were observed between SCC and AdCA. Whereas SCC
predominantly showed a Tp*C mutational signature, AdCA mainly
contained *CpG signatures. Interestingly, Tp*C mutations have
been associated with the APOBEC family of enzymes, known to be
involved in the cellular response against HPV [37].
To date, little data exists on somatic mutations in hgCIN lesions.
By mutation analysis of 48 cancer-related genes using a targeted
sequencing approach in a panel of SCCs, AdCAs and hgCIN lesions,
PIK3CA was the only gene found to be mutated in a single hgCIN
case [38]. Subsequent high-resolution melting analysis of 209
hgCIN lesions, revealed PIK3CA exon 9 hotspot mutations (p.E542K
and p.E545K) at very low levels in only 2.4% of these lesions,
suggesting that mutations of PIK3CA represent a late event during
cervical carcinogenesis. In concordance with this, low fractions of
Fig. 1. Schematic representation of HPV-mediated cervical carcinogenesis. Progression of a high-grade CIN lesion, characterized by viral oncogene expression in dividing
cells (i.e. a transforming infection), to invasive cancer results from the accumulation of DNA changes induced by HPV. High-grade CIN represents a heterogeneous stage of
disease with varying duration of existence (up to 30 years). ‘Advanced’ lesions show a cancer-like proﬁle including hypermethylation of tumour suppressor genes and
speciﬁc chromosomal alterations. Complementary somatic mutations only become detectable at the stage of invasive cancer. CIN: cervical intraepithelial neoplasia; TSG:
tumour suppressor gene.
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carcinomas, indicating PIK3CA mutations are only present in
subclones of the tumour [32,38].5. Conclusions
From the above summarised ﬁndings it becomes clear that
following an infection with hrHPV, additional (epi)genetic altera-
tions in host cell genes are crucial for the development of cervical
(pre)cancerous lesions. The clinical implications of these altera-
tions are thoroughly discussed by Steenbergen et al. [8]. The viral
oncogenes directly or indirectly trigger the deregulation of many
control mechanisms that ultimately lead to the accumulation of
genetic and epigenetic alterations. Ultimately, the right combina-
tion of (epi)genetic alterations may provide a growth advantage
and result in progression of a hgCIN to invasive cancer, a process
that is estimated to take 15–30 years [39]. The key events may in
part be different between cervical SCC and AdCA and dependent
on the hrHPV type present.
Based on the available information we propose a model (Fig. 1)
in which a transforming infection by HPV contributes to dereg-
ulation of the DNA methylation machinery, which, upon selection
may give rise to DNA methylation mediated silencing of tumour
suppressor genes. Changes in overall DNA methylation as well as
HPV-induced mitotic defects result in chromosomal instability and
aneuploidy. Both increased DNA methylation of certain gene pro-
moters and speciﬁc chromosomal alterations are primarily de-
tectable in a subset of longer existing (i.e. advanced) hgCIN lesions
that are likely to have a higher risk of progression to cancer. Mu-
tations, on the other hand, are only very rarely found in hgCIN and
in invasive cancers appear mostly restricted to speciﬁc subclones
of cancer cells. Together, these observations indicate that muta-
tions occur late in cervical carcinogenesis and are probably not
among the most key molecular events involved in the progression
of precancerous cervical lesions.
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